Immunology
Congress Materials – Michigan Rheumatism Society (MRS 2026)
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Structural Damage Progression and Clinical Response to Guselkumab in Participants With Active and Erosive Psoriatic Arthritis: Post hoc Analysis at Week 24 of the Phase 3b, Randomized, Double-blind, Placebo-controlled APEX Study
Christopher T Ritchlin, Proton Rahman, Laura C Coates, Alexa P Kollmeier, Yusang Jiang, Soumya D Chakravarty, Elizabeth Adamson, Karissa Lozenski, Arthur Kavanaugh, Philip J Mease
This document will be available after August 7th
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.